The big question is: what plasma biomarker(s) could be used to accurately predict the severity of Alzheimer's Disease (AD) progression in patients? Because such molecules would have to be secreted from neurons in the brain, diffuse into the interstitial fluid (ISF), then the CSF, and finally the plasma, we would logically expect a largely attenuated signal in blood.
Dementia is an inevitable burden for many humans, prevailing under a broad umbrella not only in neurological disorders but also as the natural process of aging. Alzheimer’s disease (AD) represents the most common disease with several stages of dementia, which progresses over time. There are no tools or therapies to cure, prevent, or slow the progression of AD.
Topics: Alzheimer's Disease